Ceritinib is used to treat ALK-positive NSCLC. Ceritinib is part of a group called ALK inhibitors. They zero in on the ALK pathway in cancer cells.
Ceritinib’s main ingredient is Ceritinib hydrobromide. You take it in 150 mg caps. The usual dose is 450 mg a day, and you take it with food.
Each bottle has 70 of those 150 mg capsules. Ceritinib’s job is to help keep the cancer from spreading and ease symptoms of ALK-positive NSCLC.
